Discretionary Pricing Under the 340B Program: The Savings Layer Most Hospitals Miss
Most discussions of the 340B program focus on the statutory discount prices established through the program's ceiling price formula. But for expansion entities managing orphan drugs, there is an additional pricing layer worth understanding: discretionary pricing.
Discretionary pricing refers to voluntary discount programs that pharmaceutical manufacturers offer to covered entities outside of the formal 340B pricing structure. For orphan drugs, this matters especially. Because expansion entities face the orphan drug exclusion, the standard 340B price is not always accessible for these medications.
Some manufacturers, however, voluntarily extend discounts on orphan-designated products to facilities that qualify and apply correctly. These programs are not publicly advertised. They vary by manufacturer, change without formal announcements, and require active enrollment or documentation to access.
For a Critical Access Hospital or Rural Referral Center with significant orphan drug utilization, missing applicable discretionary pricing programs can represent tens of thousands of dollars in lost savings annually. The drugs involved are typically high-cost specialty medications, which means the per-unit difference between a discounted and non-discounted price is substantial.
Accessing discretionary pricing requires knowing which manufacturers offer it, what documentation they require, and when their terms change. This is specialized knowledge that demands dedicated monitoring and manufacturer relationships.
340B Orphan Drug Solutions monitors discretionary pricing programs on behalf of expansion entities and ensures every applicable opportunity is captured.